ReviewProbiotics and antimicrobial proteins2026
The Role of Next-Generation Probiotics in Colorectal Cancer Pathways: Mechanisms and Therapeutic Potential.
Review in Probiotics and antimicrobial proteins, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Postbiotic-Mediated Green Synthesis of Silver Nanoparticles: Revealing Potent Antimicrobial, Anti-Biofilm, Antioxidant, and Anticancer Properties using Paenibacillus xylanexedens.Probiotics and antimicrobial proteins · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Colorectal cancer (CRC) is a second leading cause of human mortality worldwide. Due to the inconsistent effectiveness of traditional anticancer therapies, there is an increasing need for novel drug-free cancer therapy that enhances the efficacy of current treatments with minimum side effects. CRC is linked to microbiome modifications, a phenomenon termed dysbiosis, which entails the reduction and/or augmentation of certain gut bacteria and their metabolites. Administration of next-generation probiotics (NGP) may serve as an effective and accessible cancer treatment by regulating gut microbiota composition. The review provides a focused analysis of NGPs in CRC, highlighting their preventive and therapeutic roles, modulation of gut microbiota and signaling pathways, and current translational progress. Restoration of intestinal microbiota in cancer patients may promote anti-inflammatory, anticarcinogenic, immunomodulatory, and other physiologically significant pathways that exhibit high selectivity for tumor cells. The potential advantages of NGP include the modulation of intestinal microbial community and functionality, in addition to influencing the host's inflammatory response. NGPs that help maintain gut balance include Bacteroides fragilis, Akkermansia muciniphila, Propionibacterium freudenreichii, and specific strains of Clostridium spp. This review emphasizes their applicability in CRC prevention, with promising preclinical evidence from animal models. Recent evidence suggests that NGP may provide novel therapeutic approaches for CRC by facilitating physiological processes via the generation of immuno-modulatory metabolites that counteract CRC. Despite the observed positive outcomes in preclinical studies, more research concentrating on targeted strain, safe use, and dosage specificity is necessary to confirm the effectiveness and safety profile of NGP in the treatment of CRC.
Indexed as
Identifiers
40889060What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.